Egis's Unfavourable Exposure Limits AttractivenessMay 2012 | Industry Trend Analysis
BMI View: Egis' significant exposure to its domestic pharmaceutical market in Hungary will continue to damage its top- and bottom-line financials over the coming quarters. It exposure to austerity measures in other key Central and Eastern European markets will also limit its growth potential. Egis' latest set of financial results may have beaten market expectations but moderately strong sales were primarily boosted by positive currency effects due to the weakness of the Hungarian forint. Successful cost-cutting measures have benefited the bottom line, but a lot of these savings have been offset by additional payment obligations to markets including Hungary and Romania.
To read the full article, please choose one of the following options: